Pocenbrodib

CAS No. 2304372-79-8

Pocenbrodib( —— )

Catalog No. M36302 CAS No. 2304372-79-8

Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 1201 Get Quote
5MG 1587 Get Quote
25MG 2512 Get Quote
50MG 3110 Get Quote
100MG 4140 Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Pocenbrodib
  • Note
    Research use only, not for human use.
  • Brief Description
    Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
  • Description
    Pocenbrodib (compound II) is a CBP/p300 family of bromodomain inhibitor. Pocenbrodib has the potential for cancer research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2304372-79-8
  • Formula Weight
    525.57
  • Molecular Formula
    C28H32FN3O6
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    [C@H](O)(C1=NC2=C(N1[C@H]3C[C@H](C(O)=O)CCC3)C=CC4=C2CC[C@H](C)N4C(OC)=O)C5=C(OC)C=CC(F)=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. George Luke. Inhibiting cyclic amp-responsive element-binding protein (creb). WO2020190780A1.
molnova catalog
related products
  • MS645

    MS645 is an inhibitor of bromodomain-containing protein 4 (BRD4) with a Ki of 18.4 nM for BRD4-BD1/BD2.

  • NEO2734

    NEO2734 is an orally active and selective inhibitor of p300/CBP and BET bromodomain(IC50 of <30 nM for both p300/CBP and BET bromodomains).

  • OTX015

    OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4. Phase 1.